Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma.

M Coleman1, J O Armitage, M Gaynor

  • 1Division of Hematology-Oncology, New York Hospital-Cornell Medical Center, NY 10021.

Seminars in Hematology
|April 1, 1988
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.

ESMO open·2025
Same author

Characterizing different motility-induced regimes in active matter with machine learning and noise.

Physical review. E·2024
Same author

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.

ESMO open·2021
Same author

Detecting depinning and nonequilibrium transitions with unsupervised machine learning.

Physical review. E·2020
Same author

Dynamic phases, stratification, laning, and pattern formation for driven bidisperse disk systems in the presence of quenched disorder.

Physical review. E·2019
Same author

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.

Kidney cancer (Clifton, Va.)·2018

The COP-BLAM chemotherapy programs show significant success in treating advanced diffuse large cell lymphoma, with later versions achieving high remission and long-term survival rates. Prognostic factors like age and response speed are crucial for patient outcomes.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Pharmacology

Background:

  • Advanced diffuse large cell lymphoma (DLCL) requires effective combination chemotherapy.
  • Previous COP-BLAM regimens aimed for maximal tumor kill through intense multidrug therapy.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of various COP-BLAM chemotherapy programs in patients with advanced diffuse large cell lymphoma.
  • To assess the impact of infusional therapy and sequential cycles on treatment outcomes.

Main Methods:

  • Administration of sequential COP-BLAM chemotherapy programs (IA, IB, III, IV, V) to patients with advanced DLCL.
  • Utilized outpatient administration, infusional therapy, and alternating myelosuppressive and cycle-active agents.
  • Monitored complete remission (CR) rates, disease-free survival (DFS), and potential cure rates.

Related Experiment Videos

Main Results:

  • COP-BLAM IA and IB achieved 73% CR and 55% DFS.
  • COP-BLAM III demonstrated 84% CR, 76% potential cures, and 65% DFS at 50 months.
  • COP-BLAM IV resulted in 88% CR, 67% potential cures, and 64% DFS at 24 months.
  • COP-BLAM V shows preliminary promise in high-risk Hodgkin's disease.

Conclusions:

  • Sequential COP-BLAM chemotherapy programs, particularly those incorporating infusional therapy and tailored cycles, are highly effective for advanced DLCL.
  • Prognostic factors, including patient age and rapidity of response, significantly influence treatment outcomes.
  • COP-BLAM V may offer a shortened but effective treatment option for certain lymphomas.